Demographic features of study populations
Demographic feature . | n . |
---|---|
Age (y), median (range) | 54 (23-73) |
Sex (%) | |
Male | 18 (62) |
Female | 11 (38) |
Race (%) | |
Black | 8 (29) |
White | 17 (59) |
Asian | 3 (10) |
Other | 1 (3) |
Ethnicity (%) | |
Hispanic | 7 (24) |
Non-Hispanic | 22 (76) |
Disease type (%) | |
B-cell lymphomas | 7 (24) |
Burkitt | 1 (3) |
DLBCL | 1 (3) |
Follicular | 5 (17) |
T-cell lymphomas | 18 (62) |
ATLL | 6 (21) |
ALCL ALK(−) | 3 (10) |
Sezary syndrome | 2 (7) |
CTCL | 1 (3) |
CD4+ T cell | 1 (3) |
Hepatosplenic T cell | 1 (3) |
Intestinal T cell | 1 (3) |
NK T cell | 1 (3) |
PTCL | 1 (3) |
SPTL-AB | 1 (3) |
Other | 4 (14) |
Blastic plasmacytoid dendritic cell neoplasm | 1 (3) |
Hodgkin lymphoma | 3 (10) |
Prior therapies, median (range) | 3 (1-16) |
CHOP/RCHOP/CHOEP/EPOCH/hyper-CVAD | 24 (83) |
Experimental therapies: clinical trials | 11 (38) |
Gemcitabine based: GEM/GemiFOX/GemOX/GVD | 9 (31) |
HDAC inhibitors | 9 (31) |
Alkylator based: Benda/CTX/CVP | 8 (28) |
Platinum based: RICE/ICE/DHAP/ESHAP | 7 (24) |
Radiation | 7 (24) |
Biologics: bexarotene/ublituximab/Rituxan | 7 (24) |
Autologous stem cell transplant | 6 (21) |
MTX/SMILE | 5 (17) |
ABVD/ABV-COPP/MOPP | 4 (14) |
Brentuximab vedotin | 4 (14) |
Lenalidomide based | 4 (14) |
Phototherapy: light/PUVA | 3 (10) |
Pralatrexate | 2 (7) |
Allogeneic transplant | 1 (3) |
Demographic feature . | n . |
---|---|
Age (y), median (range) | 54 (23-73) |
Sex (%) | |
Male | 18 (62) |
Female | 11 (38) |
Race (%) | |
Black | 8 (29) |
White | 17 (59) |
Asian | 3 (10) |
Other | 1 (3) |
Ethnicity (%) | |
Hispanic | 7 (24) |
Non-Hispanic | 22 (76) |
Disease type (%) | |
B-cell lymphomas | 7 (24) |
Burkitt | 1 (3) |
DLBCL | 1 (3) |
Follicular | 5 (17) |
T-cell lymphomas | 18 (62) |
ATLL | 6 (21) |
ALCL ALK(−) | 3 (10) |
Sezary syndrome | 2 (7) |
CTCL | 1 (3) |
CD4+ T cell | 1 (3) |
Hepatosplenic T cell | 1 (3) |
Intestinal T cell | 1 (3) |
NK T cell | 1 (3) |
PTCL | 1 (3) |
SPTL-AB | 1 (3) |
Other | 4 (14) |
Blastic plasmacytoid dendritic cell neoplasm | 1 (3) |
Hodgkin lymphoma | 3 (10) |
Prior therapies, median (range) | 3 (1-16) |
CHOP/RCHOP/CHOEP/EPOCH/hyper-CVAD | 24 (83) |
Experimental therapies: clinical trials | 11 (38) |
Gemcitabine based: GEM/GemiFOX/GemOX/GVD | 9 (31) |
HDAC inhibitors | 9 (31) |
Alkylator based: Benda/CTX/CVP | 8 (28) |
Platinum based: RICE/ICE/DHAP/ESHAP | 7 (24) |
Radiation | 7 (24) |
Biologics: bexarotene/ublituximab/Rituxan | 7 (24) |
Autologous stem cell transplant | 6 (21) |
MTX/SMILE | 5 (17) |
ABVD/ABV-COPP/MOPP | 4 (14) |
Brentuximab vedotin | 4 (14) |
Lenalidomide based | 4 (14) |
Phototherapy: light/PUVA | 3 (10) |
Pralatrexate | 2 (7) |
Allogeneic transplant | 1 (3) |
ABV-COPP, adriamycin, bleomycin, vinblastin, cyclophosphamide, vincristine, procarbazine, prednisone; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; CHOEP, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CTCL, cutaneous T-cell lymphoma; CTX, cyclophosphamide; CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; CVP, cyclophosphamide, vincristine, prednisone; DHAP, dexamethasone, high dose cytarabine, cisplatin; DLBCL, diffuse large B-cell lymphoma; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, adriamycin; ESHAP, etoposide, solumedrol, high dose cytarabine, cisplatin; GEM, gemcitabine; GemiFOX, gemcitabine, ifosfamide, oxaliplatin; GemOX, gemcitabine, oxaliplatin; GVD, gemcitabine, vinorelbine, doxil; ICE, ifosfamide, carboplatin, etoposide; MOPP, mustargen, vincristine, procarbazine, prednisone; MTX, methotrexate; NK, natural killer; PUVA, psoralen and UV A; RCHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RICE, rituxan, ifosfamide, carboplatin, etoposide; SPTL-AB, subpanniculitis-like T-cell lymphoma alpha/beta.